Package Quantity: 1/Pkg Brand: PANOQUELL® Active Ingredient: fuzapladib sodium
Quantity
Choose a comparable product or call 1-800-225-7911 for assistance

PANOQUELL®-CA1 (fuzapladib sodium for injection) is the first FDA conditionally approved treatment for the management of clinical signs associated with acute onset of pancreatitis in dogs.

  • A fast, safe and effective treatment for the management of the inflammation associated with acute canine pancreatitis (ACP) LFA-1 activation inhibitor
  • Inhibits the infiltration of neutrophilic inflammation within the pancreas
  • Given once daily for 3 consecutive days by IV bolus injection
  • Proven to quickly reduce clinical signs and measurable values such as canine pancreas-specific lipase (Spec cpL) and C-reactive protein (CRP) associated with ACP
  • With the multi-use vial, there is the ability to treat multiple patients and there is a reduction in waste
  • Can be given in conjunction with other supportive care treatments
  • For intravenous use in dogs only
  • Can reduce time and stress often seen in the hospital setting with ACP treatment

NDC Number: 13744-0812-01 Active Ingredient: fuzapladib sodium Package Quantity: 1/Pkg Strength: 4 mg/ml when reconstituted Presentation: Powder Container Type: Vial Delivery Type: Injection Reconstitution Required: Y Contains: 1 bottle fuzapladib, 1 bottle of diluent Product Type: Anti-Inflammatory Brand: PANOQUELL®